Victory Capital Management Inc. bought a new stake in PROCEPT BioRobotics Co. (NASDAQ:PRCT – Get Rating) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 162,785 shares of the company’s stock, valued at approximately $6,762,000. Victory Capital Management Inc. owned about 0.36% of PROCEPT BioRobotics as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also made changes to their positions in the company. Point72 Hong Kong Ltd purchased a new stake in shares of PROCEPT BioRobotics in the third quarter valued at about $35,000. Russell Investments Group Ltd. purchased a new stake in shares of PROCEPT BioRobotics in the third quarter valued at about $71,000. UBS Group AG raised its holdings in shares of PROCEPT BioRobotics by 127.9% in the third quarter. UBS Group AG now owns 1,823 shares of the company’s stock valued at $75,000 after buying an additional 1,023 shares during the last quarter. Strs Ohio raised its holdings in shares of PROCEPT BioRobotics by 29.4% in the fourth quarter. Strs Ohio now owns 2,200 shares of the company’s stock valued at $91,000 after buying an additional 500 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of PROCEPT BioRobotics in the fourth quarter valued at about $125,000. 66.40% of the stock is owned by hedge funds and other institutional investors.
PROCEPT BioRobotics Price Performance
Shares of PRCT opened at $31.85 on Friday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.36 and a current ratio of 7.56. The firm’s 50-day moving average is $31.83 and its two-hundred day moving average is $36.80. PROCEPT BioRobotics Co. has a twelve month low of $25.29 and a twelve month high of $52.40.
Analysts Set New Price Targets
A number of research analysts have recently issued reports on PRCT shares. Truist Financial dropped their price target on shares of PROCEPT BioRobotics from $54.00 to $49.00 in a research note on Friday, April 28th. Bank of America dropped their price target on shares of PROCEPT BioRobotics from $52.00 to $44.00 in a research note on Friday, April 28th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, PROCEPT BioRobotics has a consensus rating of “Moderate Buy” and a consensus target price of $46.83.
Insiders Place Their Bets
In other news, CEO Reza Zadno sold 5,335 shares of the stock in a transaction that occurred on Thursday, March 16th. The shares were sold at an average price of $31.84, for a total value of $169,866.40. Following the sale, the chief executive officer now directly owns 155,791 shares in the company, valued at $4,960,385.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CFO Kevin Waters sold 7,954 shares of the stock in a transaction that occurred on Tuesday, March 7th. The shares were sold at an average price of $34.25, for a total value of $272,424.50. Following the sale, the chief financial officer now directly owns 56,860 shares in the company, valued at $1,947,455. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Reza Zadno sold 5,335 shares of the stock in a transaction that occurred on Thursday, March 16th. The shares were sold at an average price of $31.84, for a total transaction of $169,866.40. Following the completion of the sale, the chief executive officer now owns 155,791 shares in the company, valued at $4,960,385.44. The disclosure for this sale can be found here. Over the last three months, insiders have sold 36,171 shares of company stock worth $1,245,196. 19.60% of the stock is owned by company insiders.
About PROCEPT BioRobotics
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).
Further Reading
- Get a free copy of the StockNews.com research report on PROCEPT BioRobotics (PRCT)
- Big Lots Becomes A Stomach Churning Value Play
- The Melt-Up In Marvell Is On; But Don’t Chase It Higher
- Is Apple a Growth Stock or a Value Stock?
- Costco’s Earnings Call Reassure Economists, Recession Cancelled
- Hot Inflation, What It Means For The Summer Rally
Want to see what other hedge funds are holding PRCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PROCEPT BioRobotics Co. (NASDAQ:PRCT – Get Rating).
Receive News & Ratings for PROCEPT BioRobotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROCEPT BioRobotics and related companies with MarketBeat.com's FREE daily email newsletter.
